GENE ONLINE|News &
Eli Lilly Plans FDA Submission for Weight-Loss Pill Orforglipron by 2025
Eli Lilly announced that its experimental weight-loss pill, orforglipron, demonstrated significant results in a clinical trial. The company stated it intends to apply for Food and Drug Administration (FDA) approval for the drug before the end of 2025.
The findings from the trial revealed that orforglipron led to substantial weight loss among participants. Eli Lilly has positioned the drug as a potential treatment option for obesity, a condition affecting millions globally. The company has not yet disclosed specific data regarding the extent of weight loss observed during the study but emphasized its plans to move forward with regulatory submissions. If approved, orforglipron could become part of a growing market for pharmaceutical treatments targeting obesity and related health conditions.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
Date: August 7, 2025
Related posts:
DrugPatentWatch: Data Analysis Could Cut Pharma Patent Litigation Costs by 50%
Federal Equipment Company Implements Training and Auction Strategies to Support CDMOs in Pharmaceutical Manufacturing
European Commission Approves SYD-101 for Paediatric Myopia Treatment Across EU
Cilta-cel Therapy Achieves Sustained Remission in CARTITUDE-1 Trial for Relapsed Multiple Myeloma
Author
LATEST
Study Finds Acute Pancreatitis Worsens Outcomes for Pediatric Stem Cell Transplant Patients
2026-01-16
Study Explores Patient Perspectives on Frailty Screening Implementation in Emergency Departments
2026-01-16
Researchers Identify SMPDL3B as Potential Biomarker and Therapeutic Target for Myalgic Encephalomyelitis
2026-01-16
Study Explores Transcriptomic Changes in Cryopreserved Human Ovarian Tissue Using 3D Culture Techniques
2026-01-16
